Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation
This retrospective real-world study demonstrates the effectiveness and safety of efgartigimod in these four MuSK-Ab-positive, female Asian patients with exacerbation of MG, as well as in patients experiencing MC. It is important to note that efgartigimod should not be viewed as a substitute for foundational immunotherapy; rather, it is intended as a rescue treatment during exacerbations and as an adjunctive therapy in the context of long-term immunotherapy. This non-invasive approach has the potential to become another treatment option for MuSK-Ab-positive MG patients.
Authors
- Xiaofei Sun (ORCID: https://orcid.org/0000-0002-7724-6063)
- Feng Li (ORCID: https://orcid.org/0000-0001-8184-1247)
- Hongyan Zhou (ORCID: https://orcid.org/0000-0002-4210-3476)
- Huiyu Feng (ORCID: https://orcid.org/0000-0003-1153-5919)
- Cunzhou Shen
- Haiyan Wang (ORCID: https://orcid.org/0009-0001-7246-431X)
- Jiaxin Chen (ORCID: https://orcid.org/0000-0002-3507-6991)
- Fu‐Dong Shi (ORCID: https://orcid.org/0000-0002-9675-4637)
- Jiezhen Feng
- Rong Lai
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2024-11-19
- DOI
- https://doi.org/10.3389/fneur.2024.1486659
- Citations
- 8
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 2.95
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province